Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
Biomind Labs (BMND) is launching a commercial clinical trial on its proprietary mescaline-based formulation. The drug targets inflammation, which the company believes is the root cause of many forms of depression.